Japanese startup Ubie has scored $26.2 million in its first Sequence C funding spherical, participated by its new buyers Norinchukin Capital Co., NVenture Capital Ltd., Dai-ichi Life Insurance coverage Co., and Egg FORWARD. The spherical was additionally joined by its current investor SUZUKEN Co.
This brings its whole capital raised since inception to nearly $60 million.
Based in 2017, Ubie presents two AI-powered options: the Ubie AI Symptom Checker for sufferers and the AI Affected person Consumption for healthcare suppliers.
WHAT IT’S FOR
The startup plans to make use of its newest funding for its continued enlargement throughout Japan and the USA.
Particularly, will probably be used to speed up collaborations with pharmaceutical firms, in keeping with CEO and co-founder Dr Yoshinori Abe. To this point, Ubie has partnered with over 20 pharmaceutical companies in Japan and different international locations.
THE LARGER TREND
This funding occasion comes months after Ubie launched its web-based AI Symptom Checker within the US. This model comes with customised AI algorithms that take into consideration the nation’s illness developments and different regional traits.
Ubie final held a fundraising occasion in 2020 the place it raised about $19 million to scale its AI choices.